Exhibit 99.1 Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones ● Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States ● Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder successful completion of end-of ...

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Daré representing 50% of the future payments otherwise payable to XOMA Transaction allows Daré to focus on advancing Phase 3 first-in-category investigational products Ovaprene®, a potential first FDA-approved hormone-free intravaginal monthly contraceptive, and Sildenafil Cream, 3.6%, a potential first FDA-approv ...

Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it will receive a paym ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO MarDee Haring-Layton - Chief Accounting Officer Conference Call Participants Douglas Tsao - H.C. Wainright Will Hidell - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company’s Fourth Quarter Financial Results and to provide a General Business Update. This call is being recorded. My name is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-K ___________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exa ...

财务业绩 - Daré Bioscience报告2023年全年财务业绩，现金及现金等价物为1050万美元[21] - Daré在2023年实现了约280万美元的总收入，净亏损约3010万美元[22] - Daré的2023年研发费用约2150万美元，2024年预计研发费用将大幅减少[24] 产品信息 - XACIATO™（clindamycin phosphate）阴道凝胶2%已在美国上市，用于治疗细菌性阴道炎[6] - Ovaprene®无激素月经间隔避孕药候选品关键第三阶段临床研究正在美国进行招募[9] - Sildenafil Cream，3.6%用于治疗女性性唤醒障碍的临床研究已完成第二阶段会议，FDA即将提供额外反馈[13] - Daré宣布DARE-PDM1和DARE-VVA1的积极结果，分别用于治疗月经痛和性疼痛[17][19] - Daré的首个获得FDA批准的产品是XACIATO™（clindamycin phosphate）阴道凝胶2%，用于治疗12岁及以上女性患者的细菌性阴道炎[38] - Daré的产品组合还包括潜在的首创类别候选产品：Ovaprene®、Sildenafil Cream、3.6%和DARE-HRT1[38] 更新计划 - Daré将于2024年提供有关FDA反馈、第三阶段研究设计和计划的更新[15] - Daré将于2024年提供有关季度收入和上市产品XACIATO™的更新[7] - Daré将于2024年提供有关Ovaprene®和Sildenafil Cream的招募和数据更新[10][15] 行业影响力 - Daré的CEO被评为2023年Fierce Pharma生物制药领域最具影响力人物之一[39]

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting advancement of Sildenafil Cream, 3.6% (Sildenafil Cream) for the treatment of female sexual arousal disorder (FSAD) to a Phase ...

SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflec ...

分组1 - 公司专注于女性健康产品,女性健康产品占总畅销产品的27%,贡献35%的总销售额,市场仍有很多未满足需求 [10] - 公司正在推进多个潜在颠覆性的后期阶段候选药物,包括Sildenafil Cream和Ovaprene [11][13][14] - Sildenafil Cream是首个获批治疗女性性唤起障碍的产品,目标市场约2000万名患者 [17][18][19] - Ovaprene是首个无激素的月经周期性阴道避孕套,目标市场约3500万名女性 [27][29] 分组2 - 公司与领先的女性健康公司Organon和Bayer建立了商业化合作 [31] - XACIATO已在美国上市,公司将获得里程碑付款和销售提成 [33][42][43] - 公司在资金管理方面保持谨慎,正在探索各种融资方式,包括非稀释性融资 [44][46][47] 问答环节重要的提问和回答 问题1 **Catherine Novack 提问** 询问Ovaprene临床试验的更新计划和潜在的中期数据发布 [51][52][53][54][55] **Sabrina Martucci Johnson 回答** 公司计划定期发布Ovaprene临床试验的进展情况,但目前没有计划在试验完成前发布中期数据,未来会根据情况进行评估 [52][53][54][55] 问题2 **Catherine Novack 提问** 询问公司是否考虑就Sildenafil Cream寻求合作伙伴,以及合适的时机 [61][62][63][64][65] **Sabrina Martucci Johnson 回答** 公司一直在评估各种合作和融资方式,包括针对Sildenafil Cream的合作,时机将根据具体情况而定,公司将选择对股东最有利的方式 [62][63][64][65] 问题3 **Doug Tsao 提问** 询问潜在合作伙伴是否有参与Sildenafil Cream III期临床试验设计的意愿 [69][70][71] **Sabrina Martucci Johnson 回答** 公司在Sildenafil Cream临床前期工作中已经成为该领域的领导者,积累了丰富的经验,未来合作伙伴可能会对临床试验设计提出意见,但公司有信心主导该项目的发展 [70][71][72][73]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-4139823 (State or Other Jurisd ...